Slide 1: Submission of revised Investor Presentation
Date: October 28, 2024 Ref. No.: KDL/SE/104/2024-25 To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 40
Slide 2: Q2FY2025 Result Presentation
Q2FY2025 Result Presentation One of INDIA’S LARGEST Differentiated Diagnostic Service Provider October 2024
Slide 3: Q2FY2025 & H1FY25 Performance
Q2FY2025 & H1FY25 Performance
Slide 4: Krsnaa Diagnostics Operations at a Glance
Krsnaa Krsnaa Diagnostics Diagnostics Q2FY25At Operations- – aOperations Glance at a Glance Radiology Pathology India's 1st India’s 1st CAP Accreditation NABH Accredited Tele 178 in Govt. Hospital radiology HUB 121 CT/MRI Centres Processing lab 1,434 NABH NABL 3,139 Tele-Reporting Collection Centre
Slide 5: Krsnaa Diagnostics H1FY25 Financials at a Glance
Krsnaa Krsnaa Diagnostics Diagnostics H1FY25 Financial- – Glance At a Financials at a Glance In mn Growth Momentum continues: Achieving 21% YoY Revenue Growth, 48% YoY EBITDA Strengthening & 49% YoY improvement in PAT, on account of improved footfalls across our centers and enhanced operational effi
Slide 6: Krsnaa Diagnostics Q2FY25 Financials at a Glance
Krsnaa Diagnostics Q2FY25 – Financials at a Glance In mn Growth Momentum continues: Achieving 20% YoY Revenue Growth, 58% YoY EBITDA Strengthening & 87% YoY improvement in PAT on account of improved footfalls across our centers and enhanced operational efficiency Revenue from operation EBIDTA PAT Q2
Slide 7: Financial Performance Analysis
H1FY25 – EBIDTA Financial Analysis Performance In mn Existing Centre New Centre 27% 1,735 22% c 1,831 287 664 H1FY25 H1FY24 Revenue EBIDTA c Note: Considering the nature of business, financial performance is best evaluated on an annualized basis. 4 EBIDTA & EBIDTA Margin are before CSR & ESOP
Slide 8: Key Developments
—@® Key Developments
Slide 9: Strategic Investment in Apulki
Krsnaa Only – Apulki Company Strategic with Pan Investment India Presence in Both Radiology and Pathology u hc (‘ u ’), I ’s f s 01 Public Private Partnership (PPP) dedicated for cancer and cardiac care hospital. Apulki is establishing two state-of-the-art cancer and 02 cardiac 125+ bedded hospitals
Slide 10: Why Investment in Apulki
Why Only Investment Company in Apulki with Pan India Presence in Both Radiology and Pathology Margin Revenue Visibility Long term revenue visibility, as Improvement the contract of Apulki is for 30 The pricing for Apulki would be at years period with option to CGHS pricing, which would enable increa
Slide 11: Strategic Partnership: Medikabazaar and United Imaging
Strategic Only Partnership: Company United with Pan India Imaging Presence in Both& Medikaaand Radiology Bazaar Pathology FINANCING TERM PARTNERSHIP Through this partnership, krsnaa has Medikabazaar I ’s largest B2B Healthcare received special financing term, where-in procurement & supply-chain solu
Slide 12: Pan India Presence in Both Radiology and Pathology
PANCompany Only India Presence in Radiology with Pan India Presence in&Both Pathology Radiology and Pathology Well Diversified Regional Revenue Mix 13% 31% Q2FY2025 35% 21% West South North East ▪ Highest penetration across districts with presence in 150+ out of 700+ districts; still large underpene
Slide 13: Project Under Implementation
Project Only Under Company Implementation with Pan India Presence in Both Radiology and Pathology Radiology Centres Under Implementation Pathology Centres Under Implementation Total Centres Operational Under Total Centres Operational Under Implementation Implementation Uttar Pradesh 8 5 3 DMC 1 1 -
Slide 14: Growth Strategy
Growth Only Strategy Company with Pan India Presence in Both Radiology and Pathology We aim to sustain the upward trajectory of our Revenue and PAT CAGR by utilizing our existing facilities and seizing opportunities in untapped markets Tap the growing and Continue to enhance Building the Retail Digi
Slide 15: Krsnaa Diagnostics Edge
Krsnaa Only Diagnostics Company Edge with Pan India Presence in Both Radiology and Pathology ₹ Extensive Strong Scalable & Agile Cost Stakeholder Geographic Brand Equity Business Model Leadership Value Footprint Creation Centres across India with Well positioned to PPP is an asset light Ability to m
Slide 16: Financial Performance
—@® Financial Performance
Slide 17: Financial Performance
Financial Only Performance Company with Pan India Presence in Both Radiology and Pathology In mn Particulars Q2 FY 25 Q2 FY 24 Q1 FY 25 H1 FY 25 H1 FY 24 Amount % Amount % Amount % Amount % Amount % Revenue from operations 1,863 1,555 1,702 3,566 2,950 Expenses Cost of Material Consumed 449 24% 359
Slide 18: Financial Performance: Assets and Liabilities
Financial Only Performance Company with Pan India Presence in Both Radiology and Pathology (INR In Mn) Assets Sep 30, 2023 Sep 30, 2024 Liabilities Sep 30, 2023 Sep 30, 2024 Non-current assets Equity Equity share capital 156.99 161.45 Property, plant and equipment 5,562.30 6,863.38 Other equity 7,39
Slide 19: Contact Information
Contact Contact Information Information This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments